|0.899 -0.251 (-21.83%)||12-08 16:00|
|Targets||6-month :||2.21||1-year :||3.53|
|Resists||First :||1.89||Second :||3.02|
|Supports||First :||0.05||Second :||0.04|
|MAs||MA(5) :||1.28||MA(20) :||0.38|
|MA(100) :||0.18||MA(250) :||1.04|
|MACD||MACD :||0.2||Signal :||0.1|
|%K %D||K(14,3) :||45.1||D(3) :||55.3|
|52-week||High :||25||Low :||0.05|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZVSA ] has closed below upper band by 35.7%. Bollinger Bands are 1747.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||1.15 - 1.16||1.16 - 1.16|
|Low:||0.88 - 0.89||0.89 - 0.89|
|Close:||0.89 - 0.9||0.9 - 0.91|
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||44 (M)|
|Held by Insiders||3.895e+007 (%)|
|Held by Institutions||54.4 (%)|
|Shares Short||2,500 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-55.7 %|
|Return on Equity (ttm)||-2 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||-2.3 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-10 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||0|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|